Loading…
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their abili...
Saved in:
Published in: | Pharmaceuticals 2016-11, Vol.9 (4), p.69 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353 |
---|---|
cites | cdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353 |
container_end_page | |
container_issue | 4 |
container_start_page | 69 |
container_title | Pharmaceuticals |
container_volume | 9 |
creator | Catuogno, Silvia Esposito, Carla L de Franciscis, Vittorio |
description | The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies. |
doi_str_mv | 10.3390/ph9040069 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_82ce1bc9ef3c429ab5bb1748340c443a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_82ce1bc9ef3c429ab5bb1748340c443a</doaj_id><sourcerecordid>1839130446</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</originalsourceid><addsrcrecordid>eNpdkV1rFDEUhoNYbLt64R-QAW_0YmxOPiYZocLSqi1UvNleh0xyZneW2cmYzBT67027dWmFQA7Jw5OXvIS8B_qF85qejZuaCkqr-hU5AcFEqZlQr5_Nx-Q0pS2lUoGAN-SYKZ2Xqk7I-XKc7A5j-Qt9Zyf0xcrGNT4Ml9h3dxjvi9AWqw1GO-I8dS59LZZDcTv6TL8lR63tE7572hfk9sf31cVVefP75_XF8qZ0ksupVMK7ygur0NumBUYrJUArZKCZhha8t4qjZI5bTitBuQMrK_TIOGs9l3xBrvdeH-zWjLHb2Xhvgu3M40GIa2Njztaj0cwhNK7GljvBatvIpgElNBfUCZEfWJBve9c4Nzv0Docp2v6F9OXN0G3MOtwZCbWmWbEgn54EMfyZMU1m1yWHfW8HDHMyoHkNPJNVRj_-h27DHIf8VZmSmjMJSmfq855yMaQUsT2EAWoeCjaHgjP74Xn6A_mvUf4XOeufLg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1858325178</pqid></control><display><type>article</type><title>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>IngentaConnect Journals</source><creator>Catuogno, Silvia ; Esposito, Carla L ; de Franciscis, Vittorio</creator><creatorcontrib>Catuogno, Silvia ; Esposito, Carla L ; de Franciscis, Vittorio</creatorcontrib><description>The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph9040069</identifier><identifier>PMID: 27827876</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>aptamers ; Cancer ; drug delivery ; Drug delivery systems ; Ligands ; Medical research ; Neurological disorders ; Review ; targeted therapy</subject><ispartof>Pharmaceuticals, 2016-11, Vol.9 (4), p.69</ispartof><rights>Copyright MDPI AG 2016</rights><rights>2016 by the authors; licensee MDPI, Basel, Switzerland. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</citedby><cites>FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1858325178/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1858325178?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,25753,27922,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27827876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Catuogno, Silvia</creatorcontrib><creatorcontrib>Esposito, Carla L</creatorcontrib><creatorcontrib>de Franciscis, Vittorio</creatorcontrib><title>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</title><title>Pharmaceuticals</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.</description><subject>aptamers</subject><subject>Cancer</subject><subject>drug delivery</subject><subject>Drug delivery systems</subject><subject>Ligands</subject><subject>Medical research</subject><subject>Neurological disorders</subject><subject>Review</subject><subject>targeted therapy</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkV1rFDEUhoNYbLt64R-QAW_0YmxOPiYZocLSqi1UvNleh0xyZneW2cmYzBT67027dWmFQA7Jw5OXvIS8B_qF85qejZuaCkqr-hU5AcFEqZlQr5_Nx-Q0pS2lUoGAN-SYKZ2Xqk7I-XKc7A5j-Qt9Zyf0xcrGNT4Ml9h3dxjvi9AWqw1GO-I8dS59LZZDcTv6TL8lR63tE7572hfk9sf31cVVefP75_XF8qZ0ksupVMK7ygur0NumBUYrJUArZKCZhha8t4qjZI5bTitBuQMrK_TIOGs9l3xBrvdeH-zWjLHb2Xhvgu3M40GIa2Njztaj0cwhNK7GljvBatvIpgElNBfUCZEfWJBve9c4Nzv0Docp2v6F9OXN0G3MOtwZCbWmWbEgn54EMfyZMU1m1yWHfW8HDHMyoHkNPJNVRj_-h27DHIf8VZmSmjMJSmfq855yMaQUsT2EAWoeCjaHgjP74Xn6A_mvUf4XOeufLg</recordid><startdate>20161103</startdate><enddate>20161103</enddate><creator>Catuogno, Silvia</creator><creator>Esposito, Carla L</creator><creator>de Franciscis, Vittorio</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161103</creationdate><title>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</title><author>Catuogno, Silvia ; Esposito, Carla L ; de Franciscis, Vittorio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>aptamers</topic><topic>Cancer</topic><topic>drug delivery</topic><topic>Drug delivery systems</topic><topic>Ligands</topic><topic>Medical research</topic><topic>Neurological disorders</topic><topic>Review</topic><topic>targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Catuogno, Silvia</creatorcontrib><creatorcontrib>Esposito, Carla L</creatorcontrib><creatorcontrib>de Franciscis, Vittorio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJÂ Directory of Open Access Journals</collection><jtitle>Pharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Catuogno, Silvia</au><au>Esposito, Carla L</au><au>de Franciscis, Vittorio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aptamer-Mediated Targeted Delivery of Therapeutics: An Update</atitle><jtitle>Pharmaceuticals</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2016-11-03</date><risdate>2016</risdate><volume>9</volume><issue>4</issue><spage>69</spage><pages>69-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer-nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>27827876</pmid><doi>10.3390/ph9040069</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1424-8247 |
ispartof | Pharmaceuticals, 2016-11, Vol.9 (4), p.69 |
issn | 1424-8247 1424-8247 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_82ce1bc9ef3c429ab5bb1748340c443a |
source | PubMed (Medline); Publicly Available Content Database; IngentaConnect Journals |
subjects | aptamers Cancer drug delivery Drug delivery systems Ligands Medical research Neurological disorders Review targeted therapy |
title | Aptamer-Mediated Targeted Delivery of Therapeutics: An Update |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A39%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aptamer-Mediated%20Targeted%20Delivery%20of%20Therapeutics:%20An%20Update&rft.jtitle=Pharmaceuticals&rft.au=Catuogno,%20Silvia&rft.date=2016-11-03&rft.volume=9&rft.issue=4&rft.spage=69&rft.pages=69-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph9040069&rft_dat=%3Cproquest_doaj_%3E1839130446%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c535t-74dc6d4a7edabf120674187e218281f1dda73e52c3a306403c1a56ede232fd353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1858325178&rft_id=info:pmid/27827876&rfr_iscdi=true |